Business Update Positive

2026-11-09 08:55

- Morepen Laboratories has entered the U.S. prescription generics market with the launch of Desloratadine Tablets USP, 5 mg through its wholly owned U.S. subsidiary, Morepen Bio Inc. - The company submitted its first ANDA to the U.S. FDA for Sitagliptin Phosphate Tablets and plans further U.S. generic filings leveraging its API strengths.

Business Update Positive

2026-11-09 08:54

Morepen Laboratories has entered the U.S. prescription generics market through its wholly owned U.S. subsidiary, Morepen Bio Inc., by launching Desloratadine Tablets USP, 5 mg. - The company leverages its established API supply strengths to extend into finished-dosage medicines and U.S. distribution. - Morepen also submitted its first ANDA to the U.S. FDA for Sitagliptin Phosphate Tablets and plans further generic filings and expansion into high-potency APIs.

Governance Neutral

2026-10-31 18:15

- Mr. Nishant Jayesh Doshi resigned as Vice President - Corporate Finance & Investor Relations and Senior Management Personnel of Morepen Laboratories Limited. - Effective date of resignation is October 31, 2026. - Resignation is to pursue a new professional opportunity.

Governance Neutral

2026-10-27 19:43

- Morepen Laboratories Limited informed the exchange about a change in Senior Management Personnel effective from October 27, 2026. - Mr. Charanjeet Chitakara was promoted from General Manager (Quality Control) to Assistant Vice President (Quality Control). - Mr. Vivan Prashar was promoted from Assistant Vice President (Projects & Engineering) - Operations (API) to Vice President (Projects & Engineering) - Operations (API).

Business Update Positive

2026-10-27 13:49

Morepen Laboratories released its investor presentation for Q2 & H1 FY27, highlighting strong growth in revenue and earnings. - Q2 FY27 Revenue reported at ₹755 Cr (up 117% YoY) and EBITDA at ₹132 Cr (up 273% YoY). - H1 FY27 Revenue reached ₹1,330 Cr with PAT surging to ₹145 Cr. - CDMO segment scaled up significantly, accounting for 52% of API + CDMO revenue in Q2.

Financials Positive

2026-10-27 13:49

Q2 FY27 Revenue: Rs. 755 Cr, up 81% YoY EBITDA: Rs. 132 Cr, up 273% YoY PAT: Rs. 89 Cr, up 117% YoY EBITDA Margin: 17.45%, up 897 bps YoY H1 FY27 Revenue reached Rs. 1,330 Cr (up 57% YoY) and PAT reached Rs. 145 Cr (up 177% YoY). CDMO momentum and medical devices franchise drove strong performance with capacity expansion ongoing towards 800 KL.

Financials Positive

2026-10-27 13:33

Q2 FY27 Consolidated Revenue ₹746.50Cr vs ₹411.58Cr (▲81% YoY) EBITDA ₹123.12Cr vs ₹56.52Cr (▲118% YoY) PAT ₹88.89Cr vs ₹41.04Cr (▲117% YoY) EBITDA Margin 16.5% vs 13.7% (▲276bps)

Business Update Positive

2026-10-14 18:26

- Hon’ble High Court of Himachal Pradesh at Shimla quashed the Show Cause Notice (SCN) issued by the GST authorities seeking recovery of ₹117.94 Crore towards excess GST refund. - The High Court disposed of the writ petition entirely in favor of Morepen Laboratories Limited. - There is no adverse financial or operational impact on the company due to this favorable order.

Routine Neutral

2026-09-28 16:47

- Trading window will close from October 1, 2026. - Closure is for considering unaudited financial results for the quarter and half-year ended September 30, 2026. - Window will reopen 48 hours after the declaration of financial results.

Business Update Positive

2026-09-28 08:58

- Morepen Laboratories submitted its first U.S. ANDA to the USFDA for Sitagliptin Tablets USP (25 mg, 50 mg, and 100 mg) on September 25, 2026. - This milestone marks the expansion of the company's established API and CDMO expertise into integrated finished dosage development and regulatory filing. - The innovator product, Januvia, recorded worldwide sales of approximately US$1.604 billion in 2025. - The company estimates 24-36 months from submission to progress towards approval and commercial supply.

Business Update Neutral

2026-09-22 16:18

- Morepen Laboratories received an independent 'CRISIL ESG 60' rating, categorized as 'Adequate', for fiscal 2026 from Crisil ESG Ratings & Analytics Limited on September 21, 2026.

Business Update Positive

2026-09-07 08:50

- Morepen Laboratories Limited completed the first phase of its manufacturing capacity expansion program ahead of schedule. - Installed reactor capacity for API and CDMO increased from 535 KL to 614 KL. - This enhances manufacturing readiness for CDMO supplies and supports existing API business.

Governance Positive

2026-09-02 13:45

- Notice of 41st Annual General Meeting (AGM) to be held on Saturday, September 26, 2026, via Video Conferencing/OAVM. - The Board recommended a final dividend of ₹0.20 per equity share for the financial year 2025-26, with the record date set as Saturday, September 19, 2026. - Mr. Sanjay Suri's designation changed from Whole-Time Director to Managing Director, effective July 1, 2026. - Mr. Sushil Suri re-appointed as Chairman & Managing Director for three years, from October 20, 2026, to October 19, 2029. - Timeline for hiving off the Medical Devices Business into Morepen Medipath Limited extended until the 42nd Annual General Meeting in 2027, at a value of ₹197.10 Crores.

Business Update Positive

2026-08-06 17:04

- Morepen Laboratories Limited (parent company) subscribed to a rights issue of its wholly-owned subsidiary, Morepen RX Limited (MRX), for 2,00,00,000 equity shares of ₹10 each, totaling ₹20 Crores. - This investment aims to strengthen MRX's capital base and support its business operations. - The parent company continues to hold 100% of MRX's equity share capital.

Financials Positive

2026-08-04 14:38

- Consolidated Revenue ₹570.13 Cr vs ₹425.24 Cr (▲34.07% YoY) - EBITDA ₹87.72 Cr vs ₹28.58 Cr (▲207.08% YoY) - PAT ₹56.35 Cr vs ₹11.41 Cr (▲394.0% YoY) - EBITDA Margin 15.38% vs 6.72% (▲866 bps)

Financials Positive

2026-08-04 14:22

- Consolidated Revenue ₹570.13 Cr vs ₹425.24 Cr (▲34.07% YoY) - EBITDA ₹87.72 Cr vs ₹28.58 Cr (▲206.99% YoY) - PAT ₹56.35 Cr vs ₹11.41 Cr (▲393.99% YoY) - EBITDA Margin 15.38% vs 6.72% (▲866bps) - Board recommended final dividend for FY26, with record date on September 19, 2026. - Re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a period of three years effective from October 20, 2026. - Approved the extension of the timeline for hiving off the Medical Devices Business into a subsidiary, Morepen Medipath Limited, on a slump sale basis.

Routine Neutral

2026-08-04 14:13

New Filing detected. See link for details.

Financials Positive

2026-08-04 14:07

- Revenue ₹575.31Cr vs ₹429.33Cr (▲34% YoY) - EBITDA ₹87.72Cr vs ₹28.57Cr (▲207% YoY) - PAT ₹56.35Cr vs ₹11.41Cr (▲394% YoY) - EBITDA Margin 15.25% vs 6.65% (▲860bps)

Financials Positive

2026-08-04 13:51

- Consolidated Revenue ₹570.13Cr vs ₹425.24Cr (▲34.1% YoY) - EBITDA ₹82.53Cr vs ₹24.17Cr (▲241.5% YoY) - PAT ₹56.35Cr vs ₹11.41Cr (▲394.0% YoY) - EBITDA Margin 14.47% vs 5.68% (▲879bps) - Board declared a record date of September 19, 2026, for determining members eligible to receive final dividend for the financial year ended March 31, 2026. - Board approved the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a 3-year term from October 20, 2026, subject to AGM approval. - Board approved extending the timeline for hiving off the Medical Devices Business into Morepen Medipath Limited on a slump sale basis, subject to AGM approval. - The 41st Annual General Meeting (AGM) will be held on September 26, 2026.

Business Update Neutral

2026-07-23 18:49

- Wholly-owned subsidiary "Morepen Labs - FZCO" changed its name to "Morepen Labs FZE" effective July 20, 2026. - This change is due to its migration from IFZA to JAFZA, with JAFZA issuing new documents on July 23, 2026.

MOREPENLAB

Morepen Laboratories Limited

Price Chart

Filing History

Unlock Full History